MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma

Treatments with GSK-J4 were found to be associated with the induction of apoptosis and increased expression of pro-inflammatory cytokines. As such our results demonstrate that whilst members of the Kdm6 family are overexpressed in MPM they may not be suitable candidates for therapy and may elicit a cytokine storm.
Comments Off on Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma

Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study

CONCLUSION: The omission of the elective irradiation of the whole ipsilateral pleural space allowed dose escalation from 49 Gy to more than 58 Gy in 4 of 12 chemonaive MPM patients. This strategy may form the basis for nonsurgical radical combined modality treatment of MPM.
Comments Off on Does selective pleural irradiation of malignant pleural mesothelioma allow radiation dose escalation? : A planning study

Large primary pleural synovial sarcoma with severe dyspnea: a case report

He was treated with pleuropneumonectomy, radiotherapy, and adjuvant chemotherapy. Although the best treatment for this rare condition has not been defined, we thought that tumor resection and adjuvant therapy were appropriate to control the disease in this case.
Comments Off on Large primary pleural synovial sarcoma with severe dyspnea: a case report

HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

Moreover, EP reduced HMGB1 serum levels in mice and inhibited the growth of MM xenografts. Our results indicate that EP effectively hampers the malignant phenotype of MM, offering a novel potential therapeutic approach to patients afflicted with this dismal disease.
Comments Off on HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

With a relatively large database of 17 phase II trials and 716 patients from Cancer and Leukemia Group B and North Central Cancer Treatment Group, we conducted statistical analyses and found that there is no evidence to suggest that PFS is a valid surrogate endpoint for OS for malignant mesothelioma. Future research work is needed to find alternative surrogate endpoints for OS.
Comments Off on Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

3-(2-deoxy-β-D-erythro-pentafuranosyl)pyrimido[1,2-α]purin-10(3H)-one deoxyguanosine adducts of workers exposed to asbestos fibers

3±0. 1 (SE) in 171 controls (p.
Comments Off on 3-(2-deoxy-β-D-erythro-pentafuranosyl)pyrimido[1,2-α]purin-10(3H)-one deoxyguanosine adducts of workers exposed to asbestos fibers

What is Mesothelioma?

Learn more about this fatal cancer, including the causes, symptoms, and treatments for both pleural and peritoneal tumors of the mesothelium at our parent site MesotheliomaCenter.

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

CONCLUSIONS: Long-term regional chemotherapy was associated with improved survival in patients with MPM. In this rare disease, additional phase 2 investigations are suggested.
Comments Off on Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia

Notably, a TG2-selective irreversible inhibitor that reacts with the intracellular active form of TG2, but not a non-cell-permeable inhibitor, significantly compromised cell viability in MPM spheroids. Understanding the expression and function of TG2 in the adaptation to the hypoxic environment may provide useful information for novel promising therapeutic options for MPM treatment.
Comments Off on Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review

CONCLUSIONS: From the available literature no serum or pleural fluid biomarker was identified that could be recommended currently for routine clinical practice. However, a falling serum soluble mesothelin might correlate with treatment response and improved survival.
Comments Off on Prognostication and monitoring of mesothelioma using biomarkers: a systematic review

Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation

These findings indicate that PDPN is a diagnostic marker as well as a pathogenetic regulator that promotes MPM progression by increasing cell motility and inducing focus formation. Therefore, PDPN might be a pathogenetic determinant of MPM dissemination and aggressive growth and may thus be an ideal therapeutic target.
Comments Off on Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation